Abstract: A movable workbench for performing work under low temperature, such as ?80° C. or below. The movable workbench includes: a worktable including a workspace forming member for providing a workspace for work at low temperature and a refrigerant-reservoir for containing a refrigerant, and disposed on a base with a moving member; the workspace forming member including side and bottom walls providing a workspace with an upper surface opening; the upper surface of the workspace being open on the upper side of the worktable; the refrigerant-reservoir accommodating the bottom wall of the workspace forming member so that a gas phase in the workspace is cooled when the refrigerant is provided in the refrigerant-reservoir and the bottom wall of the workspace forming member is subsequently cooled; and the moving member disposed on a bottom surface of the base so that the worktable is movable with the refrigerant-reservoir filled with the refrigerant.

Abstract: Disclosed is a method for producing pluripotent stem cell-enriched human dental pulp-derived cells. The method is characterized in that it includes (a) culturing a dental pulp suspension in a feeder cells-culture vessel containing feeder cells whose proliferative ability is suppressed, on a membrane having micropores that can block passage of the feeder cells and supported in the feeder cells-culture vessel in a manner to prevent the lower side face thereof from contacting with the feeder cells, thereby preventing direct contact with the feeder cells, and, (b) a step for recovering the cells proliferating on the membrane.

Abstract: Disclosed is a fusion protein containing a brain-derived neurotrophic factor (BDNF). The fusion protein is a fusion protein of BDNF and a specific range of human anti-transferrin receptor antibody, which makes BDNF administered into the blood able to pass through the blood-brain barrier.

Abstract: Disclosed are a means to convert compounds having physiological or pharmacological activity and unable to pass through the blood-brain barrier into a form that allows them to pass through the blood-brain barrier, and compounds converted thereby. The means is an anti-human transferrin receptor antibody and the converted compounds are molecular conjugates between physiologically active protein or pharmacologically active low-molecular-weight compounds and an anti-human transferrin receptor antibody.

Abstract: Disclosed are a novel anti-human transferrin receptor antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 6 and 7 that can pass through the blood-brain barrier, a fusion protein comprising a protein necessary to be brought into function in the central nervous system and the antibody, and method of their production. The fusion protein comprises amino acid sequences of an anti-human transferrin receptor antibody that recognizes an amino acid sequence selected from the group consisting of SEQ ID NOs:1, 2, and 3, and of other protein that is bound thereto on the C-terminal side.

Abstract: Disclosed is a method which enables semiquantitative or quantitative determination of the ratio between cysteine and formylglycine residues in a protein. The method includes (a) a step of labeling the protein (i) with a halogen-substituted carboxylic acid, (ii) with a halogen-substituted carboxylic acid amide, and (iii) with a halogen-substituted carboxylic acid and then with hydrazine, or with a halogen-substituted carboxylic acid and then by oximation, (b) a step of digesting each labeled protein to provide a corresponding mixture of peptide fragments, (c) a step of subjecting each mixture to reverse phase chromatography to separate the peptide fragments from each other to produce a chromatogram, (d) a step of comparing the produced chromatograms with each other to identify the peak corresponding to the peptide fragment that contained a cysteine residue and the peak corresponding to the peptide fragment that contained a formylglycine residue.

Abstract: The pharmaceutical injection device includes a pharmaceutical syringe mounting portion (3) provided within a main body case (2) and to which a pharmaceutical syringe (4) is removably mounted, a piston (5) provided movably with respect to the pharmaceutical syringe (4) mounted to the pharmaceutical syringe mounting portion (3), a drive mechanism (6) for driving the piston (5), a controller (7) that is electrically connected to the drive mechanism (6), a display section (35) that is connected to the controller (7), and an encoder (26) that is connected to the controller (7) and detects the amount of the pharmaceutical remaining inside the pharmaceutical syringe (4). The controller (7) displays a warning on the display section (35) recommending removal of the pharmaceutical syringe (4) from the pharmaceutical syringe mounting portion (3) when the presence of a pharmaceutical is detected by the encoder (26).

Abstract: Disclosed is a method for production of recombinant human DNase I which is of such high purity as may be directly used as a medical drug. The method includes the steps of; culturing recombinant DNase I-producing mammalian cells, subjecting a culture supernatant to an anion-exchange column chromatography, subjecting to a column chromatography employing as solid phase a material having affinity for phosphate group, subjecting to a cation-exchange column chromatography, and subjecting to a dye affinity column chromatography.

Abstract: Disclosed are a novel expression vector for efficient expression of recombinant proteins in mammalian cells, a mammalian cell transformed with the vector, and a method for production of the mammalian cell. The expression vector is an expression vector for expression of a mammalian protein and includes a gene expression regulatory site, and a gene encoding the protein downstream thereof, and an internal ribosome entry site further downstream thereof, and a gene encoding a glutamine synthetase further downstream thereof, and a dihydrofolate reductase gene downstream of either the same gene expression regulatory site or another gene expression regulatory site in addition to the former.

Abstract: This pharmaceutical injection system is provided with a pharmaceutical injection device, a charging device, a detector, and an alarm section. The pharmaceutical injection device has a main body case and a pharmaceutical syringe mounting portion provided within the main body case and to which a pharmaceutical syringe is removably mounted. The pharmaceutical injection device is placed in the charging device, and the charging device has a charger for charging the pharmaceutical injection device. The detector is provided to the pharmaceutical injection device and/or the charging device and detects whether or not the pharmaceutical syringe has been mounted to the pharmaceutical syringe mounting portion. The alarm section is connected to the detector and emits an alarm when it is detected that the pharmaceutical syringe has been mounted onto the pharmaceutical syringe mounting portion.

Abstract: Disclosed is a method for production of recombinant human alpha-galactosidase A (rh alpha-Gal A) in a large scale, with a high purity. The method comprises the steps of (a) culturing rh alpha-Gal A-producing mammalian cells in a serum-free medium, (b) collecting culture supernatant, (c) subjecting the culture supernatant to anion-exchange column chromatography, (d) to hydrophobic column chromatography, (e) to a column chromatography employing as solid phase a material having affinity for phosphate group, (f) to cation-exchange column chromatography, and (g) to gel filtration column chromatography, in the order.

Abstract: Provided are a novel medium for expressing glycoproteins by culturing cells and a method for producing glycoproteins by culturing cells in said medium. Further provided are a medium comprising uridine and N-acethyl-D-mannosamine for the use of expression of a glycoprotein by culturing cells and a method for producing glycoproteins by culturing cells in said medium.

Abstract: This pharmaceutical injection device comprises a main body case (2) that has an injection needle insertion and retraction opening (1); pharmaceutical syringe mounting portion (3) that is provided within the main body case (2); a piston (5) that is provided movably with respect to a pharmaceutical syringe (4) that is mounted to the pharmaceutical syringe mounting portion (3); a drive mechanism (6) that drives the piston (5); a controller (7) that is electrically connected to the drive mechanism (6); and a display section (35) that is electrically connected to the controller (7). The controller (7) updates the display content that is displayed on the display section (35) according to the number of times the drive mechanism (6) has been driven, and saves this updated display content in a memory (51), so that when the drive mechanism (6) has been driven a specific number of times, the display contents during the various instances of drive that were saved in the memory (51) are combined.

Abstract: Disclosed is a method for production of recombinant human iduronate 2-sulfatase (rhI2S) (the 26th to 550th amino acids of SEQ ID NO: 10) in a large scale, with a high purity, and mannose 6-phosphate residues. The method comprises the steps of (a) culturing rhI2S (the 26th to 550th amino acids of SEQ ID NO: 10)-producing mammalian cells in a serum-free medium, (b) collecting culture supernatant, (c) subjecting the culture supernatant to cation-exchange column chromatography, (d) to dye affinity column chromatography, (e) to anion-exchange column chromatography, and (f) to a column chromatography employing as solid phase a material having affinity for phosphate group, and (g) to gel filtration column chromatography, in the order.

Abstract: [Problem] To provide a method for producing human corneal epithelial sheet, wherein the human corneal epithelial-derived cells obtained by culturing human corneal epithelial cells are cultured on an amnion substrate. [Solution] A method for culturing human corneal epithelial cells using mesenchymal stem cells as the feeder cells; and a method for culturing human corneal epithelial cells using a medium containing a ROCK inhibitor, a phosphodiesterase inhibitor, a MAP kinase inhibitor and a TGF-? receptor inhibitor in various combinations.

Abstract: This pharmaceutical injection system is provided with a pharmaceutical injection device, a charging device, a detector, and an alarm section. The pharmaceutical injection device has a main body case and a pharmaceutical syringe mounting portion provided within the main body case and to which a pharmaceutical syringe is removably mounted. The pharmaceutical injection device is placed in the charging device, and the charging device has a charger for charging the pharmaceutical injection device. The detector is provided to the pharmaceutical injection device and/or the charging device and detects whether or not the pharmaceutical syringe has been mounted to the pharmaceutical syringe mounting portion. The alarm section is connected to the detector and emits an alarm when it is detected that the pharmaceutical syringe has been mounted onto the pharmaceutical syringe mounting portion.

Abstract: This pharmaceutical injection device comprises a main body case (2) that has an injection needle insertion and retraction opening (1); pharmaceutical syringe mounting portion (3) that is provided within the main body case (2); a piston (5) that is provided movably with respect to a pharmaceutical syringe (4) that is mounted to the pharmaceutical syringe mounting portion (3); a drive mechanism (6) that drives the piston (5); a controller (7) that is electrically connected to the drive mechanism (6); and a display section (35) that is electrically connected to the controller (7). The controller (7) updates the display content that is displayed on the display section (35) according to the number of times the drive mechanism (6) has been driven, and saves this updated display content in a memory (51), so that when the drive mechanism (6) has been driven a specific number of times, the display contents during the various instances of drive that were saved in the memory (51) are combined.

Abstract: The pharmaceutical injection device includes a pharmaceutical syringe mounting portion (3) provided within a main body case (2) and to which a pharmaceutical syringe (4) is removably mounted, a piston (5) provided movably with respect to the pharmaceutical syringe (4) mounted to the pharmaceutical syringe mounting portion (3), a drive mechanism (6) for driving the piston (5), a controller (7) that is electrically connected to the drive mechanism (6), a display section (35) that is connected to the controller (7), and an encoder (26) that is connected to the controller (7) and detects the amount of the pharmaceutical remaining inside the pharmaceutical syringe (4). The controller (7) displays a warning on the display section (35) recommending removal of the pharmaceutical syringe (4) from the pharmaceutical syringe mounting portion (3) when the presence of a pharmaceutical is detected by the encoder (26).

Abstract: Means for improving the success rate of pregnancy on the basis of blastocyst transfer is disclosed. The means comprises an agent for promoting pregnancy in blastocyst transfer comprising the supernatant of the culture which is obtained by culturing a human embryo in a medium until the embryo develops into a blastocyst. Also disclosed are a method for production of the agent, as well as a method for promoting pregnancy comprising; culturing a human embryo in a medium until the human embryo develops into a blastocyst, injecting a composition comprising the supernatant of the culture into the uterine cavity of a patient who is to undergo blastocyst transfer, and then transferring the blastocyst to the recipient.

Abstract: The objective is to find compounds which have an activity to improve the success rate of pregnancy and implantation in blastocyst transfer in mammals, to provide a method of producing and using the compounds, and to provide a pregnancy-promoting agent. Disclosed is a pregnancy-promoting agent containing one or more lysophosphatidic acids selected from the group consisting of LPA-C16:0, LPA-C16:1, LPA-C18:0, LPA-C18:1 and LPA-C18:2.